Eligibility criteria will focus on English-speaking adults ≥21 years old, with moderate-to-severe CLBP treated with ≥30 mg/day of morphine-equivalent opioid dose for ≥3 months. The study will implement a limited set of exclusionary criteria to ensure a diverse sample, from which findings can be generalized.